What the trial was testing
The trial enrolled 16 patients with duchenne muscular dystrophy. The study was sponsored by NS Pharma and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was initial testing (phase 2). Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
About 6% of normal dystrophin produced — and timed motor tests improved.
JAMA Neurology · 2020 · NCT02740972
These findings — that dystrophin levels with viltolarsen plus improved timed motor tests in DMD — were published in the JAMA Neurology and represent the headline result of the study.
Researchers tracked outcomes across 16 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with duchenne muscular dystrophy, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Viltolarsen (Viltepso) is FDA-approved and available now for Duchenne muscular dystrophy in patients whose DMD gene mutation can be treated by exon-53 skipping (about 8% of DMD cases). It is a weekly IV infusion. Ask a pediatric neurologist about genetic testing to determine if exon skipping fits.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open duchenne muscular dystrophy trials
Vasodilator and Exercise Study for DMD (VASO-REx)
Examining two strategies as potential adjuvant therapies for Duchenne muscular dystrophy (DMD); aerobic exercise training (to induce adaptations in skeletal muscle and improve cardiovascular health) and tadalafil, an FDA-approved vasodilator (to optimize blood flow and muscle perfusion which is impaired and often overlooked in DMD). Target: improved muscle function, vascular health, and DMD treatment.
Gamified Occupational Therapy for Adolescents With Duchenne Muscular Dystrophy
This research aims to improve the quality of life, occupational performance, occupational satisfaction and emotional health of young people with Duchenne muscular dystrophy compared to the classical occupational therapy program. The findings are planned to shed light on the development of new and effective strategies in the rehabilitation of adolescents with Duchenne muscular dystrophy.